CHTR three-lens brief
Evidence-based stock research on CHTR. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 29.7pp over 30 days. · Trading at 6% of its 52-week range — deep in the lower band.
- Trading at 6% of its 52-week range — deep in the lower band.
- Underperforming SPY by 29.7pp over 30 days.
- P/E of 4.7 — trading at a value multiple.
- Analyst mean target $249.25 — 43% above current (16 analysts).
- Debt-to-equity of 459.5 — balance-sheet-heavy.
CHTR closed at $173.79 (+1.19%) as of 2026-05-04. Market cap: $24.54B. P/E (trailing) 4.7. Positives: p/E of 4.7 — trading at a value multiple.; analyst mean target $249.25 — 43% above current (16 analysts).. Concerns: trading at 6% of its 52-week range — deep in the lower band.; underperforming SPY by 29.7pp over 30 days.. Last quarter: Revenue $13.60B, net income $1.16B, free cash flow $2.40B.
Why three lenses on CHTR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CHTRacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CHTR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CHTR brief"></iframe>